7 recruiting, 5 not yet recruiting, 5 unknown, 4 active not recruiting. 23 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 23 | Recruiting 7, Not yet recruiting 5, Unknown 5, Active not recruiting 4, Completed 2 |
| Phase 2 | 3 | Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
Follow pyrotinib: new trials by email Literature Review of pyrotinib trials Research Report on pyrotinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer Fulvestrant, Pyrotinib, Dalpiciclib - Metastatic Breast Cancer (MBC), HER2-Positive Breast Cancer | Phase 3 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 226 | 2026-11-01 | 2026-10-23 |
| Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC Docetaxel, Pyrotinib, Trastuzumab (Herceptin) - Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Phase 3 | Recruiting | Shanghai Jiao Tong University School of Medicine | 220 | 2026-07-01 | 2026-09-01 |
| Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer Afatinib + Toripalimab, Dalpiciclib + Pyrotinib, Camrelizumab + Apatinib - Esophageal Squamous Cell Carcinoma | Phase 2 / Phase 3 | Not yet recruiting | Peking University Cancer Hospital & Institute | 90 | 2026-07-01 | 2026-06-17 |
| Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Cancer Pyrotinib 320mg po qd d1-d21 q3w and Trastuzumab 600mg IH d1 q3w Combined with Dalpicicli 125mg po gd d1-d21 q4w, Pyrotinib 320mg po qd d1-d21 q3w and Trastuzumab 600mg IH d1 q3w Combined with Docetaxel 75mg/m² ivgtt d1 q3w, - Breast Cancer | Phase 3 | Recruiting | Fudan University | 502 | 2025-02-12 | 2026-05-29 |
| The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study pyrotinib - HER2 Positive Breast Cancer, Pyrotinib Treatment | Phase 2 / Phase 3 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 964 | 2024-04-30 | 2025-05-06 |
| Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel, Epirubicin or doxorubicin, cyclophosphamide, paclitaxel - Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer | Phase 3 | Active not recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 160 | 2024-01-17 | 2026-10-27 |
| Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial disitamab vedotin, Pyrotinib, trastuzumab - HER2-positive Metastatic Breast Cancer, First-line Treatment | Phase 3 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 312 | 2023-09-06 | 2024-02-26 |
| Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer pyrotinib - Breast Cancer Invasive | Phase 3 | Recruiting | RenJi Hospital | 488 | 2023-06-01 | 2025-11-18 |
| Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer Pyrotinib, Trastuzumab, Paclitaxel - Breast Cancer | Phase 3 | Not yet recruiting | Fudan University | 876 | 2023-05-06 | 2023-05-03 |
| A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane SHR-A1811, Pyrotinib in combination with Capecitabine. - HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane | Phase 3 | Active not recruiting | Jiangsu HengRui Medicine Co., Ltd. | 381 | 2022-08-04 | 2025-08-22 |
| Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab Trastuzumab plus chemotherapy, Trastuzumab in combination with pyrotinib plus chemotherapy - HER2-positive Breast Cancer, Metastatic Breast Cancer | Phase 3 | Unknown | Fudan University | 240 | 2021-09-15 | 2022-04-26 |
| Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy Pyrotinib, Trastuzumab - Breast Cancer | Phase 3 | Not yet recruiting | Shengjing Hospital | 450 | 2021-08-01 | 2021-07-22 |
| Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway Inetetamab, Rapamycin, Pyrotinib - Breast Cancer | Phase 3 | Not yet recruiting | Peking Union Medical College | 270 | 2021-02-02 | 2021-02-03 |
| Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer Trastuzumab, Pertuzumab, Nab paclitaxel - HER2+ Breast Cancer | Phase 3 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 120 | 2021-01-01 | 2022-06-23 |
| Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer Fulvestrant combined with Pyrotinib, Capecitabine combined with Pyrotinib - Breast Cancer | Phase 3 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 516 | 2020-10-14 | 2020-11-30 |
| Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy Pyrotinib, Docetaxel - Non-squamous NSCLC, HER2 Exon 20 Mutation | Phase 3 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 151 | 2020-09-11 | 2025-12-19 |
| Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer Pyrotinib, Epirubicin, Cyclophosphamide - Breast Cancer | Phase 2 / Phase 3 | Active not recruiting | Hebei Medical University Fourth Hospital | 113 | 2020-03-01 | 2026-01-07 |
| Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer pyrotinib - Locally Advanced Breast Cancer | Phase 3 | Recruiting | RenJi Hospital | 316 | 2019-12-16 | 2025-09-11 |
| A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer Pyrotinib, Placebo - Breast Cancer | Phase 3 | Active not recruiting | Jiangsu HengRui Medicine Co., Ltd. | 2135 | 2019-07-12 | 2026-08-17 |
| A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer Pyrotinib, Trastuzumab, Docetaxel, Placebo, Trastuzumab, Docetaxel - Metastatic Breast Cancer | Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 590 | 2019-04-22 | 2022-11-23 |
Showing 20 of 23. Sign in to see all of them.
Breast Neoplasms (12) · Esophageal Squamous Cell Carcinoma (1)
Jiangsu HengRui Medicine Co., Ltd. (7) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (4) · Fudan University (3) · RenJi Hospital (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · Hebei Medical University Fourth Hospital (1) · Peking Union Medical College (1) · Peking University Cancer Hospital & Institute (1) · Shanghai Jiao Tong University School of Medicine (1) · Shengjing Hospital (1)
China (21) · Australia (1) · Belgium (1) · France (1) · Germany (1) · Italy (1) · Poland (1) · Russia (1) · South Korea (1) · Spain (1) · Taiwan (1) · Turkey (Türkiye) (1) · United States (1)
Ying Wang (2) · Cai-Gang Liu, MD (1) · Chang Gong, Prof (1) · Fei Ma, MD (1) · Hongxia Wang, Chief physician (1) · Jiani Wang, M.D. (1) · Jin Yang, Doctor (1) · Jinsong Lu (1) · Wei Shi, MD,PhD (1) · Wenjin Yin, M.D. (1) · Zhimin Shao (1)
PMID 33328035, PMID 33581774, PMID 36135045, PMID 36575513, PMID 37907210, PMID 39024777, PMID 41839514, PMID 42385760